A STUDY FOR PROSTATE CANCER -PARTIAL RESPONSE TO HORMONE THERAPY
This study is for patients with prostate cancer that is only partially responding to hormone therapy. Abiraterone acetate is a hormonal tablet that has been approved by the Food and Drug Administration (FDA) for more advanced prostate cancer patients who have received chemotherapy.
The purpose of this study is to find out what effects good and/or bad, abiraterone acetate has on patients with prostate cancer. The effect of the prostate cancer will be measured by a blood test (prostatic specific antigen or PSA). Treatment will consist of 4 abiraterone acetate tablets a day. Abiraterone acetate must be taken orally one hour before a meal or two hours after a meal any time up to 10:00pm every day. Prednisone is a type of drug called a corticosteroid. One prednisone tablet will be taken twice a day. This is a standard treatment for prostate cancer. Patients will continue taking abiraterone acetate and prednisone as long as their disease does not get worse and side effects do not become too severe.
Patients must have adeno cancer of the prostate. Prior radiation therapy or surgery is ok provided > 28 days since completion and recovery from side effects. No spread of cancer to the brain.
Michael Garrison, MD